PT-141

What Is PT‑141 (Bremelanotide)?

PT‑141, also known as Bremelanotide, is a synthetic peptide developed as a melanocortin receptor agonist. It originates from structural modifications of Melanotan‑2, designed to enhance selectivity and therapeutic potential. Unlike phosphodiesterase inhibitors (e.g., sildenafil), PT‑141 acts centrally on neuroendocrine pathways rather than peripherally on vascular smooth muscle.

Mechanism of Action

PT‑141 binds to melanocortin receptors (MC3R and MC4R) in the central nervous system. Activation of these receptors modulates neural circuits involved in sexual desire and arousal. By influencing hypothalamic pathways, PT‑141 enhances libido and sexual motivation without directly altering blood flow. This central mechanism distinguishes it from vasodilatory agents, making it particularly relevant for conditions involving sexual desire rather than erectile function alone.

Research & Clinical Data

PT‑141 has undergone extensive clinical evaluation, leading to FDA approval in 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Clinical trials demonstrated significant improvements in sexual desire scores and reduced distress associated with HSDD. Investigational studies also explored its potential in male sexual dysfunction, though regulatory approval for this indication has not been granted. Reported side effects include nausea, flushing, and transient increases in blood pressure.

Purity & Quality

Pharmaceutical‑grade peptide material. Certificate of Analysis available per batch. Regulatory status: FDA‑approved for HSDD in women; investigational in other contexts.

Classification & Handling Class: Synthetic melanocortin receptor agonist | Source: Analog of Melanotan‑2 | Administration: Subcutaneous injection | Storage: 2–8°C refrigerated, protect from light | Regulatory: FDA‑approved (HSDD), investigational otherwise